Answers are grounded in this paper and cite their sources.
Proof-of-concept evaluation of a microarray patch for delivering multiple antibodies, suggesting its potential for HIV prevention in young populations.
patch units for each bnAb resulted in systemic exposure by the first collection time point of 3 h, reaching maximal concentrations by day 3 of up to 68 μg/mL. These preliminary findings suggest that the MN patch platform may serve as a promising alternative to injectable bnAb formulations for HIV prevention and treatment, particularly in neonates and infants, although further investigation is required to establish its clinical utility. Additionally, the solid-state MN formulation of bnAbs may eliminate the need for cold-chain storage or distribution, making the patch particularly suitable for use in resource-limited settings.
No takes yet. Share an insight, caveat, or question.
Peet et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: